Bioengineered Exosomes for Cancer Stem Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and profiling cancer biomarkers from circulating exosomes are limited by low sensitivity and high cost, particularly for high-throughput molecular profiling, and fail to effectively target cancer stem cells for therapy.
Innovation Solution
The development of micro flow profile-based cancer biomarkers and bioengineered exosomes that express a fusion protein with a cancer stem cell targeting peptide, allowing for the detection and targeting of specific cancer cell populations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If electron microscopy is used to assess exosome structure and size, then high-resolution imaging is achieved, but the method is neither convenient nor affordable for high throughput molecular profiling
Solution Approach 1:
The patent replaces electron microscopy (a complex mechanical/optical system requiring vacuum and specialized equipment) with flow cytometry technology that uses light scattering and fluorescent detection. This substitution maintains the ability to detect exosome physical characteristics while enabling high-throughput analysis of thousands of particles per second, making the system both convenient and affordable for clinical applications.
Solution Approach 2:
The patent introduces fluorescently labeled antibodies as intermediaries that bind to specific exosome surface markers. These antibodies serve as mediators between the exosomes and the flow cytometry detection system, allowing molecular profiling through fluorescent signal detection rather than direct imaging, thereby enabling high-throughput analysis.
2Quantity of substance
If nanoparticle tracking analysis is used to measure particle size, then size distribution is obtained, but the method cannot differentiate between vesicles within a size range of 5× orders of magnitude due to low dynamic range
Solution Approach 1:
The patent applies local quality by using multiple detection parameters (side scatter, forward scatter, and multiple fluorescent channels) to characterize exosomes rather than relying solely on size measurement. This allows differentiation of vesicles with similar sizes based on their unique surface marker expression profiles, providing precise identification despite limited size range dynamic range.
3Measurement precision
If conventional diagnostic methods are used to detect cancer biomarkers, then detection is achieved, but sensitivity and cost-effectiveness for high throughput profiling are insufficient
Solution Approach 1:
The patent employs exosome surface markers themselves as the detection targets, eliminating the need for complex sample preparation or enrichment steps. The flow cytometry system directly detects and profiles these markers on intact exosomes, providing high sensitivity detection while maintaining cost-effectiveness through automated high-throughput processing of clinical samples.
4Reliability
If existing therapeutic approaches are used to target cancer cells, then treatment is provided, but cancer stem cells are not effectively targeted leading to therapy resistance
Solution Approach 1:
The patent applies local quality by engineering exosomes to display specific targeting ligands on their surface that recognize cancer stem cell markers. This localized targeting capability allows the therapeutic exosomes to specifically bind to and deliver payloads to cancer stem cells while leaving other cell types unaffected, thereby eliminating therapy resistance without compromising overall treatment efficacy.
Data Source
AI summary
This invention is related to use of exosomes for biomarker analysis for early detecting and characterizing of disease progression of cancer. Further, the invention provides bioengineered exosomes for use in methods of targeting and treating cancer.